Emma Walmsley, GSK CEO (Credit: Fang Zhe/Xinhua/Alamy Live News)

GSK to SCO­TUS: Don't take up 'skin­ny' gener­ic drug la­bel case

GSK made clear to the US Supreme Court on Fri­day that it should not re­vive its case against Te­va Phar­ma­ceu­ti­cals re­gard­ing so-called “skin­ny” gener­ic drug la­bels, where cer­tain in­di­ca­tions are carved out so gener­ics can come to mar­ket more quick­ly.

In op­po­si­tion to Te­va’s pe­ti­tion last month, call­ing on SCO­TUS to pro­tect the long­stand­ing prece­dent of skin­ny gener­ic la­bels, GSK now claims that this case does not present threats to “gener­ic com­pa­nies who op­er­ate prop­er­ly un­der the law of in­duced in­fringe­ment as ap­plied to gener­ic drug la­bels—’skin­ny’ or not. And, it con­cerns cir­cum­stances high­ly un­like­ly to be re­peat­ed, as well as reg­u­la­tions and poli­cies FDA has changed mul­ti­ple times.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.